Loading
A phase 1/2 trial of Nivolumab, Docetaxel, PM8002 in cervical cancer and colorectal cancer, run by Bristol-Myers Squibb, now recruiting.
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04895709 by Bristol-Myers Squibb, with 1109 participants planned, started 2021-05-27 and due to reach its primary completion in 2031-08-31. Interventions recorded: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig. Conditions listed: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares PM8002, Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Nivolumab.